EARLY HEMATOPOIESIS
The hematopoietic and cardiovascular organ systems are the first to emerge during embryogenesis because the embryo requires a functional heart, vascular system, and blood for survival and growth in the early post-implantation period. Blood cell development in the embryo depends on gastrulation and mesoderm formation. Mesodermal cells contribute to the heart, the aorta in the embryo proper, formation of hematopoietic cells in yolk sac and vascular interconnection in the embryo. 1 Embryonic hematopoiesis in mice begins after gastrulation at embryonic day 6 (E6), when mesodermal cells commit to becoming hematopoietic cells. 2 The sequential sites for hematopoiesis during embryonic development then include yolk sac, the aorta-gonad-mesonephros (AGM) region, placenta, fetal liver, spleen, and finally bone marrow. 3 Yolk sac, a bilayer structure of mesoderm and endoderm-derived cell layers, is the initial site for blood cell formation. The first hematopoietic precursors derive from mesoderm that gives rise to the hemangioblast, a bipotential precursor for blood and endothelium that enters the yolk sac to initiate primitive hematopoiesis across E7-E7.5. Blood cells produced at this time are primitive hematopoietic cells consisting mainly of large nucleated red blood cells. 4 The presence of definitive hematopoietic progenitors then marks the start of a second wave of blood cell production on day E8.5. 5 However, the microenvironment in the yolk sac does not support the differentiation of definitive hematopoietic progenitors. These therefore exit the yolk sac via the vitelline veins. Following transient appearance in the AGM region, HSC are seen to colonize fetal liver passing through umbilical cord vessels of the placenta where they contribute to robust expansion and definitive hematopoiesis.
HSC then appear in the fetal liver at E11.5 where they undergo proliferation and differentiation, with maximum expansion of HSC across E15.5-E16.5, followed by a decline in cell numbers. 6 CFU-E and proerythroblasts prevail in early fetal liver, whereas myeloid and lymphoid progenitors accumulate at later stages. Modification of the liver microenvironment during fetal development occurs in preparation for HSC expansion and lineage differentiation 7 , consistent with phenotypic changes in HSC across different developmental stages. 8 Bone development begins at E12.5 as mesenchymal condensations are observed. Briefly, mesenchymal progenitor cells first give rise to chondrocytes that create a cartilaginous framework for bone. Chondrocytes are later replaced by osteoblastic cells that build up calcified bone through endochondral ossification to form the bone marrow cavity. 9 Vascular invasion into the bone then facilitates the circulation and seeding of HSC. Clonogenic hematopoietic activity in bone marrow can be found at ~E17.5 and persists throughout postnatal life. 10 Hematopoiesis in fetal spleen occurs from E13 until the first weeks of the postnatal period. Hematopoietic progenitors from fetal liver migrate to fetal spleen at E13-E14 and undergo proliferation and differentiation to give mature blood cells. In contrast to fetal liver, fetal spleen does not have significant hematopoietic activity. 11 Hematopoiesis in fetal liver depends on expansion of progenitors, while hematopoiesis in fetal spleen relies on immediate hematopoietic precursors derived from fetal liver which home directly to spleen. Special microenvironments or niches in fetal spleen appear to restrict or favor the development of particular blood cell lineages.
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PROPERTIES OF HEMATOPOIETIC STEM CELLS
In adult humans, bone marrow is the major hematopoietic organ producing more than 10 9 mature blood cells per day. Due to the short half-life of mature cells, continuous production of cells depends on the ability of HSC to self-renew and differentiate to give all blood cell types. 13 In the steady-state, specialized niches in bone marrow provide an optimal microenvironment for maintenance of HSC by regulation of their self-renewal and differentiative capacity, and conservation of their multipotency throughout cell division.
14 Self-renewal is driven intrinsically by gene expression and modulated through HSC interaction with extrinsic cues in the environment. HSC niches are crucial regulators which determine whether symmetric or asymmetric cell division occurs. 15 In terms of differentiation to give a diversity of APC, the myeloid pathway is of particular Studies now show that HSC can enter and circulate through the lymphatic system. The egress of HSC from bone marrow into extramedullary tissues depends on sphingosine-1-phosphate receptor (S1P 1 ) (Figure 2 ). HSC also use S1P 1 , to migrate across lymphatic vessels and so restore specialized myeloid cells in peripheral tissues. 42 
NICHES FOR HEMATOPOIESIS ARE DISTRIBUTED
Several niches have been described as sites for HSC maintenance, including endosteum of bone and vascular niches in bone marrow and spleen. 47, 48 In adult mice, the majority of HSC reside within osteoblastic and vascular niches in bone marrow where most hematopoietic activity occurs, whilst smaller numbers reside in vascular niches in other tissues.
Bone marrow niches contain specialized cells that provide membrane-bound and secreted growth factors to support HSC growth. 
HEMATOPOIESIS LEADING TO A DISTRIBUTED PATTERN OF MYELOID AND DENDRITIC CELLS IN MULTIPLE TISSUES
Hematopoiesis leading to APC formation now appears to reflect a complex set of developmental pathways originating from progenitors in bone marrow, leading to a diverse range of cells in different states of development within tissue sites such as bone marrow, liver, spleen and other lymphoid and non-lymphoid organs. 78 DC emerge from bone marrow progenitors, but the exact progenitors that give rise to DC and how they relate to known progenitors of lymphoid and myeloid cells in vivo is still under investigation (Figure 1 ).
Recent developmental studies show that DC subsets and monocytes/macrophages are generated along a myeloid pathway. Figure 1) . 35 , 37 Data such as these supports the concept that development of monocytes and macrophages is separated from that of DC before these cell types migrate into peripheral lymphoid tissues.
Multiple DC subsets have now been identified in tissues around the body. Their immune capacity varies in terms of ability to take up antigen and presence of inflammatory stimuli. In thymus, DC derive from an intrathymic lymphoid progenitor and represent a specialized subset important in creating a self-tolerant T cell repertoire 78 . In murine spleen, several subsets are recognized including cDC and pDC (Figure 1 ), each phenotypically and functionally distinct. Conventional DC are small, non-granular cells comprising two subsets of CD8α + and CD8α -cDC. 81 Counterpart cells can also be found in humans, free of infection and inflammation. 82 The majority of DC in spleen are CD8α -cDC with only ~20% cDC of CD8α + phenotype. 83 The CD8α + cDC are localised in the T-cell rich areas or periarteriolar lymphatic sheath (PALS) of spleen, while the CD8α − cDC are found in the marginal zone.
CD8α
− cDC can migrate into the T-cell zone upon activation with bacterial lipopolysaccharides (LPS). 84, 85 Plasmacytoid DC have strong capacity to secrete type-1 interferon (IFN-α) upon viral or bacterial infection, and express CD11c, B220, CD36, CD4, CD68, and MHC-II on their cell surface. The function of pDC is linked to their expression of TLR-7 and TLR-9 which detect viral nucleic acid in early endosomes. 86 Monocytes can also be induced to differentiate in vitro under the influence of inflammatory cytokines like GM-CSF and TNF-α to give monocyte-derived DC (mo-DC). 
EXTRAMEDULLARY SITES FOR MYELOPOIESIS OF DC
DC can also develop within peripheral tissue sites and this has clearly been demonstrated for Langerhans cells. Cells of host origin were found several months after bone marrow transplantation 77 , indicating that skin Langerhans cells are derived from tissue-restricted myeloid progenitors. Thus, DC development from progenitors within peripheral tissue sites might be possible given the distribution of HSC within tissues, and the potential for hematopoietic niches in multiple tissue sites. However, the extent to which this happens is not yet fully understood. In particular, spleen appears to support extramedullary hematopoiesis for development of tissue-specific APC. In humans and mice, steady statespleen contains cDC and pDC which are maintained by the replenishment of pre-DC, or precursors of cDC and pDC which derive from progenitors in bone marrow. We now present evidence that distinct dendritic-like cells appear to arise in spleen from endogenous selfrenewing progenitors (Figure 1) . 95 In vitro studies from this lab showed that continuous long-term stromal cultures (LTC) of spleen support production of distinct dendritic-like cells which are large cells expressing CD11c, CD11b, and MHC-I, but not MHC-II. 96 Since these cells resembled immature myeloid DC, they were named LTC-DC. [96] [97] [98] [99] [100] The phenotype of cells produced has remained stable over years of culture with characteristic expression of CD11c, CD11b, CD80, CD86, MHC-I, CD205 but not MHC-II CD8α or B220. 96, 100 Gene expression studies have shown that LTC-DC express genes encoding several cell surface molecules expressed by DC. 101, 102 LTC are distinct from other in vitro cultures for DC production in that stromal cells support DC production without addition of exogenous inflammatory cytokines, reflecting the capacity of the spleen stromal cells to support DC haematopoiesis. 103 The continual production of immature myeloid DC in LTC led to the hypothesis that hematopoietic stem or progenitor cells are maintained within LTC. 104, 105 Ongoing investigations have now supported that hypothesis.
Recently it was shown that LTC-DC have an in vivo counterpart cell, distinguishable from other DC subtypes on the basis of marker expression. 106 These cells are distinct from cDC by their higher endocytic activity, absence of MHC-II expression, and their RelBindependent development. 107, 108 They are also phenotypically and functionally distinct from monocytes. 106 The in vivo counterpart of LTC-DC, termed 'L-DC' has now been identified in both adult and neonatal spleen, and these cells possess highly endocytic activity, and can cross-present antigens to CD8 + T cells, with very limited ability to stimulate CD4 + T cell responses. 106 The inability of L-DC to induce a helper T cell response is likely due to the absence or low MHC-II expression on these cells. 100 LTC-DC and L-DC are readily distinguished from monocytes which cannot cross-present antigen to CD8 + T cells. 105, 106 Hematopoietic progenitors in LTC and their counterparts in vivo have been investigated in order to substantiate the development of L-DC as a distinct APC in the context of the spleen microenvironment. Based on the finding that a population of small cells is maintained in LTC, which reflect Lin -c-kit + Sca-1 + progenitors 109 , the question was raised as to whether HSC or MPP could serve the role as L-DC progenitors in spleen. 95 HSC derived from spleen 104 and bone marrow 105 have now been shown to act as progenitors of L-DC in LTC.
When these same subsets of HSC from spleen or bone marrow were adoptively transferred into lethally irradiated mice there was a bias favouring production of L-DC over other DC subsets in spleen. 104, 105 These data raise the possibility that APC can develop in spleen from endogenous self-renewing HSC and have tissue-specific function perhaps related to bloodborne antigens. Further studies are underway to gain complete understanding of the development of this putative novel DC subset in the splenic context.
CONCLUSION
Indeed, there is much to be learned about tissue niches for HSC and about tissue-specific hematopoiesis for production of APC, before their importance in tissue-specific inflammation and immunity can be interpreted and considered in terms of immunotherapy. Indeed, a role for self-renewing tissue-specific progenitors in production of tissue-specific APC during the steady-state and during inflammation can be justified in terms of tissue-specific immunity reflecting some level of diversification and compartmentalisation of the immune response. HSC migration into extramedullary tissues. The S1P level in tissues is lower due to
